Expert Review of Molecular Diagnostics最新文献

{"title":"Emerging precision diagnostics in genitourinary cancers.","authors":"Agnese Orsatti, Liliana Raimundo, Fernanda Fernandes-Pontes, Carmen Jeronimo, Rui Henrique, Costantino Ricci, João Lobo","doi":"10.1080/14737159.2026.2747682","DOIUrl":"10.1080/14737159.2026.2747682","url":null,"abstract":"<p><strong>Introduction: </strong>Genitourinary tumors comprise distinct entities with different epidemiological background, molecular alterations, and clinical outcomes, underlining the need for precision diagnostics.</p><p><strong>Areas covered: </strong>Recent advances in molecular technologies have facilitated the increasing use of molecular testing in routine diagnostics. These tests have important roles in diagnosis, risk stratification, and therapeutic tailoring, and are both tissue-based and liquid biopsy-based. Examples include 1) high-end (epi)genomic arrays, such as mRNA-based arrays for prostate cancer; 2) noninvasive circulating biomarkers (DNA mutations or DNA methylation) in bladder cancer, and serum/plasma microRNA (micrcoRNA-371a-3p) testing in testicular germ cell tumors; 3) as well as targeted assays focused on immunohistochemistry and fluorescence in situ hybridization (FISH) for renal and penile cancers. In this review, we cover the application of these tests in routine practice at a molecular pathology lab.</p><p><strong>Expert opinion: </strong>These tests are at different stages of development and establishment in routine practice. As molecular testing increases, so does the relevance of pre-analytics, sample selection, and morphological assessment, which are key for achieving reliable results. Integration of molecular tests is set to contribute to precision medicine in genitourinary cancers, contributing to better selection of patients for targeted therapies. Centralization of techniques, human resources, and resources is critical to establish effective molecular testing frameworks for the community.</p>","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":" ","pages":"1-19"},"PeriodicalIF":4.3,"publicationDate":"2026-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149192231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic review of the impact of germline mutations from unrelated bone marrow donors on post-allogeneic transplantation.","authors":"Giovana Paola Zaccarias Bemvides, Raquel Rodrigues Dos Santos, Milena Eloisa Ribeiro, Matheus Braga, Daniel Caligari, Aleia Harumi Uchibaba Yamanaka, Laura Vitória Perocco, Sarah Pagliarini E Silva, Giovana de Rossi Palma, Mariana de Souza Terron, Quirino Alves de Lima Neto, Jeane Eliete Laguila Visentainer","doi":"10.1080/14737159.2026.2745676","DOIUrl":"10.1080/14737159.2026.2745676","url":null,"abstract":"<p><strong>Introduction: </strong>Germline mutations are screened for in patients with haematological diseases, and their investigation is crucial for accurate diagnosis and treatment, including allogeneic hematopoietic stem cell transplantation (HSCT). However, unrelated donors are not tested for any mutation. The objective of this systematic review was to search for articles that studied germline mutations from unrelated donors on post-allogeneic transplantation.</p><p><strong>Methods: </strong>Six researchers searched for studies in four databases. STREGA was used to analyze bias. Abstracts available, English language, studies in humans, and the disclosure of unrelated HSCT were the inclusion criteria. <i>In vitro</i>, <i>in silico</i>, in animals and children; case reports, editorials, reviews, letters, comments to the editor, related donors, and studies not attending the objective were excluded . The systematic review was registered on PROSPERO (CRD420251040572).</p><p><strong>Results: </strong>883 articles were found, and after following inclusion and exclusion criteria and the PRISMA statement, five studies were selected. The authors identified germline mutations in <i>TGFβ1, IFNL4, ALDH2,</i> and <i>TLR1-2-4</i> that were associated with overall survival, non-relapse mortality, treatment‑related mortality, infection deaths, and graft-versus-host disease.</p><p><strong>Conclusions: </strong>It was possible to understand the impact of unrelated donors that are <i>IFNL4</i>-positive, <i>TLR1</i> rs5743551 G/G, and <i>TLR4</i> rs11536889 G/G on post allogeneic HSCT.</p>","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":" ","pages":"1-9"},"PeriodicalIF":4.3,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149106306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MRSA nasal PCR as a prevalence-dependent stewardship tool in hospitalized children: a structured review.","authors":"Mustafa Bakir, Rima Shrestha","doi":"10.1080/14737159.2026.2749580","DOIUrl":"https://doi.org/10.1080/14737159.2026.2749580","url":null,"abstract":"<p><strong>Introduction: </strong>Empiric anti-methicillin-resistant Staphylococcus aureus (MRSA) therapy is common in hospitalized children with severe pneumonia or suspected sepsis. MRSA nasal polymerase chain reaction (PCR) is increasingly used to support de-escalation, but its central metric, the negative predictive value (NPV), is often quoted without the prevalence on which it depends.</p><p><strong>Areas covered: </strong>PubMed, EMBASE, and the Cochrane Library were searched from January 2018 to April 2026. Twenty-seven sources were synthesized; the pediatric diagnostic-accuracy and stewardship studies and the in-window meta-analyses were appraised with QUADAS-2, EPOC, or AMSTAR-2. We examine why NPV is high in children, the prevalence above which a negative swab no longer rules out infection, performance by syndrome, and the pediatric implementation and cost literature, and propose a prevalence-conditioned framework for prospective evaluation.</p><p><strong>Expert opinion: </strong>The pediatric evidence is observational, and no study was designed to test whether PCR-guided de-escalation is safe. A negative swab is a defensible rule-out aid in severe or complicated pneumonia and selected low-prevalence intensive care sepsis, but not in skin, soft-tissue, or osteoarticular infection. Because NPV depends on prevalence, programs should measure the proportion of children with the target syndrome who have culture-confirmed MRSA infection locally before applying a published NPV.</p>","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149179953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel serum four-biomarker biosignature and field-deployable colloidal gold strip for accurate identification of subclinical and active tuberculosis.","authors":"Jingyuan Feng, Hongfei Duan","doi":"10.1080/14737159.2026.2744694","DOIUrl":"10.1080/14737159.2026.2744694","url":null,"abstract":"<p><strong>Background: </strong>Current TB diagnostics fail to detect subclinical and paucibacillary cases, hindering End TB Strategy goals. We validated a novel serum four-biomarker biosignature and developed a colloidal gold strip for accurate subclinical and active TB identification.</p><p><strong>Methods: </strong>A total of 280 participants (HC, PN, STB, ATB; <i>n</i> = 70 each) were enrolled. Serum PDGFC, CXCL9, CXCL11, and CCL1 were measured by ELISA in training (<i>n</i> = 200) and external validation (<i>n</i> = 80) cohorts. Six machine‑learning algorithms built diagnostic models. A four-plex colloidal gold strip with simplified visual criteria was developed and compared against smear, TB DNA, and IGRA.</p><p><strong>Results: </strong>All biomarkers were significantly elevated in STB/ATB versus HC/PN (<i>p</i> < 0.001), confirming Mtb-specific responses. Logistic regression achieved 97.5% validation sensitivity. The strip using a '≥2 positive lines' criterion yielded 96.0% sensitivity, 95.0% specificity, 95.5% accuracy, and outperformed conventional tests, effectively identifying smear-negative subclinical TB.</p><p><strong>Conclusions: </strong>This biosignature is a robust TB diagnostic tool. The companion strip offers a rapid, sputum-free, instrument-minimal solution for decentralized screening, bridging biomarker discovery and field application in resource-limited settings.</p>","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":" ","pages":"1-12"},"PeriodicalIF":4.3,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149135539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Salivary nanobiosensors for oral diseases: from biomarker discovery to clinical translation in precision dentistry.","authors":"Camellia Kianbakht, Maryam Ghelichli, Amir Attaran Khorasani, Jamshid Hashemi, Kioumars Maraghehmoghaddam, Nooshin Mohtasham","doi":"10.1080/14737159.2026.2745670","DOIUrl":"10.1080/14737159.2026.2745670","url":null,"abstract":"<p><strong>Introduction: </strong>Current diagnostic approaches to oral disease have limitations, highlighting the need for rapid, sensitive, and accessible technologies for routine clinical use. Biosensors can evaluate a wide range of biomarkers in oral conditions, including periodontal diseases, oral cancer, dental caries, oral infections, and peri-implant diseases.</p><p><strong>Areas covered: </strong>We present a clinical perspective on salivary biosensors for oral diseases, focusing on biomarker discovery and technological advances, with particular emphasis on challenges and solutions. Integrating biosensors with artificial intelligence, smartphones, and digital health platforms holds promise for saliva-based diagnostics in modern dentistry. These technologies support continuous monitoring through teledentistry, thereby facilitating precision dentistry. Bridging the gap between laboratory innovation, clinical validation, regulatory approval, and commercialization will be essential for the broader adoption of oral biosensors.</p><p><strong>Expert opinion: </strong>The use of wearable intraoral and portable POC biosensors could increase their clinical applicability in the future. Current limitations include long sensor response times, the computational demands of data processing, and reduced model performance across diverse patient populations. Future efforts should focus on efficient on-device data analysis and on developing robust systems that incorporate advances in both material and digital technologies, while ensuring manufacturability, user comfort, and sustained patient compliance.</p>","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":" ","pages":"1-16"},"PeriodicalIF":4.3,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149106250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microfluidic approaches to next- generation sequencing library preparation: innovations, clinical integration and point-of-care settings.","authors":"Anuja Thakur, Satish Kumar Dubey, Sanket Goel","doi":"10.1080/14737159.2026.2741059","DOIUrl":"10.1080/14737159.2026.2741059","url":null,"abstract":"<p><strong>Introduction: </strong>Next-generation sequencing (NGS) has revolutionized genomics by enabling high-throughput, cost-effective analysis of nucleic acids for both research and clinical use. Despite advances in sequencing technology, library preparation remains a major bottleneck owing to high reagent consumption, labor-intensive workflows, long hands-on-time, and susceptibility to human error.</p><p><strong>Areas covered: </strong>This review examines recent advances in microfluidic NGS library preparation across four platform types-: continuous-flow systems, droplet microfluidics, digital microfluidics (DMF), and integrated lab-on-chip devices. These technologies reduce reagent consumption by 10 to 200 times, enables high-quality libraries from picogram-scale DNA or even single cells, and automate complex workflows within enclosed systems. Their applications in liquid biopsy, pathogen detection, prenatal testing, and epigenomic profiling demonstrate considerable clinical promise. However, fabrication complexity, lack of standardization, biofouling, and high instrument costs hinder widespread adoption, particularly in resource-limited settings. Advancements in AI, thermal control, long-read sequencing, and portable microfluidics are helping to overcome these issues.</p><p><strong>Expert opinion: </strong>Microfluidic library preparation can streamline NGS workflows by improving automation, reproducibility, and accessibility, broadening sequencing use in research, clinical diagnostics, and point-of-care settings.</p>","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":" ","pages":"1-26"},"PeriodicalIF":4.3,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149069406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated proteomics and metabolomics for predicting cardiometabolic risk in pregnant women living with HIV: current evidence and future directions.","authors":"Ahizechukwu C Eke, George U Eleje, Mahmoud U Sani, Ifeanyichukwu U Ezebialu, Faisal S Dankishiya, Ibrahim S Sodangi, Ibrahim Y Ibrahim, C William Wester, Muktar H Aliyu, David R Graham","doi":"10.1080/14737159.2026.2741065","DOIUrl":"10.1080/14737159.2026.2741065","url":null,"abstract":"<p><strong>Introduction: </strong>Pregnant women living with HIV (PWLWH) experience cardiometabolic risk across pregnancy and postpartum, including hypertensive disorders of pregnancy (HDP), gestational diabetes mellitus (GDM), dyslipidemia, obesity, and later metabolic disease. This heterogenous biology reflects gestational adaptation, HIV-associated immune adaptation, antiretroviral therapy (ART), placental function, and underlying cardiometabolic susceptibility. Integrated proteomic-metabolomic prediction studies in PWLWH remain scarce, positioning current evidence as a foundation for biomarker discovery and prospective validation.</p><p><strong>Areas covered: </strong>This review evaluates molecular and biomarker evidence from PWLWH alongside broader pregnancy literature informing proteomic and metabolomic discovery. Approaches include mass-spectrometry-based proteomics and metabolomics, affinity-based platforms including Olink and SomaScan, nuclear magnetic resonance, targeted assays, and multi-omics integration using regression, network, machine learning, and latent-factor methods. Emphasis is placed on inflammatory, endothelial, angiogenic, lipid, amino-acid, mitochondrial, and immune-metabolic pathways relevant to HDP, GDM, dyslipidemia, and postpartum cardiometabolic risk.</p><p><strong>Expert opinion: </strong>Integrated proteomics and metabolomics offer near-term value for mechanistic discovery and reproducible molecular risk signatures. Translation requires longitudinal cohorts, measured ART exposure, standardized pre-analytics, independent validation, and improvement beyond clinical risk factors. High burden settings additionally require resource-appropriate sampling, simplified targeted assays, local laboratory capacity, sustainable bioinformatics, demonstrable clinical utility, and scalable translational strategies.</p>","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":" ","pages":"1-18"},"PeriodicalIF":4.3,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13677058/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149069245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual germline <i>BRCA</i> and mismatch-repair mutations: a narrative review.","authors":"Rui Chen, Chuang Ge, Fang Yuan, Kaiwen Fu, Xingtao Long, Ke Wu, Lifeng Wang","doi":"10.1080/14737159.2026.2721422","DOIUrl":"10.1080/14737159.2026.2721422","url":null,"abstract":"<p><strong>Introduction: </strong>Multilocus inherited neoplasia alleles syndrome (MINAS) can pair a germline pathogenic <i>BRCA1/2</i> variant with a pathogenic mismatch-repair (MMR) variant, but current guidelines manage the two inherited pathways separately.</p><p><strong>Areas covered: </strong>We searched PubMed, Embase, the American Society of Clinical Oncology Library, European Society for Medical Oncology OncologyPro, and Society of Gynecologic Oncology library from 2011 to 17 May 2026. It distinguishes a dual germline carrier from single-track, dual-defective, and biomarker-discordant tumors. For mismatch-repair immunohistochemistry (IHC)-deficient but microsatellite-stable results, particularly with isolated MSH6 loss, we propose technical review followed by a validated orthogonal assay when needed. The evidence for poly(ADP-ribose) polymerase inhibitor (PARPi) plus immune checkpoint inhibitor (ICI) therapy is assessed through the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) hypothesis and TOPACIO, MEDIOLA, and DUO-E.</p><p><strong>Expert opinion: </strong>Management should combine gene-specific surveillance with tumor-level biomarkers and shared decision-making. Treatment should not be inferred from dual germline status alone, and no phase III trial has predefined dual carriers as a treatment stratum.</p>","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":" ","pages":"789-804"},"PeriodicalIF":4.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148790061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Theranostic innovation in infectious lung diseases: integrating biotechnology and nanotechnology for precision medicine.","authors":"Ameneh Jafari, Asma Manzari-Tavakoli, Maryam Manzari Tavakoli, Seyed MohammadReza Hashemian, Hamidreza Jamaati, Maryam Akhtari, Payam Tabarsi, Marzieh Omrani","doi":"10.1080/14737159.2026.2714060","DOIUrl":"10.1080/14737159.2026.2714060","url":null,"abstract":"<p><strong>Introduction: </strong>Infectious lung diseases, such as pneumonia, tuberculosis, COVID-19, influenza, and emerging fungal infections, are major causes of illness and death worldwide. Traditional methods have serious limitations such as diagnostic delays, antimicrobial resistance, and non-targeted therapy. Theranostics, unifying diagnosis and therapy, offers a precision medicine solution for real-time, individualized pulmonary care.</p><p><strong>Areas covered: </strong>This review explores biotechnological and nanotechnological synergies in pulmonary theranostics. Biotech tools include CRISPR-Cas for pathogen detection, non-coding RNAs (ncRNAs) as biomarkers/modulators, and monoclonal antibodies (mAbs) for targeted neutralization. Nanotech platforms feature nanosensors and SERS for early diagnosis, plus diverse nanocarriers enabling targeted drug/gene/vaccine delivery, controlled release, and imaging. Case studies across infectious lung diseases demonstrate real-world applications. We also address safety, manufacturing scalability, regulatory complexity, and economic barriers.</p><p><strong>Expert opinion: </strong>This convergence marks a paradigm shift toward personalized pulmonary medicine. Future success demands smart, multi-stimuli-responsive nanoplatforms, AI-driven predictive modeling, and closed-loop systems linking real-time diagnostics to adaptive therapies. Translational priorities include standardized preclinical models, clear combination-product regulations, and cost-effectiveness data. Ultimately, interdisciplinary collaboration among material scientists, molecular biologists, clinicians, and regulatory experts is essential to bridge bench-to-bedside gaps and realize clinical impact.</p>","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":" ","pages":"805-828"},"PeriodicalIF":4.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148668669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"LINC00673 upregulation and rs9914618 polymorphism: associations with risk and prognosis of lung squamous cell carcinoma.","authors":"Xingshu Zhang, Fen Wang, Licai Zhang, Liquan Qiu, Jijun Xue","doi":"10.1080/14737159.2026.2719602","DOIUrl":"10.1080/14737159.2026.2719602","url":null,"abstract":"<p><strong>Background: </strong>The specific effect of the LINC00673 rs9914618 single nucleotide polymorphism (SNP) on lung squamous cell carcinoma (LUSC) remains unclear. This study aims to evaluate its association with LUSC susceptibility and prognosis.</p><p><strong>Materials and methods: </strong>We recruited 305 LUSC patients and 336 healthy controls. LINC00673 expression was measured by qRT-PCR. The rs9914618 genotype was determined using TaqMan assays. Disease-free survival was estimated by Kaplan-Meier analysis. Multivariate Cox regression yielded hazard ratios with 95% confidence intervals.</p><p><strong>Results: </strong>LINC00673 expression was significantly upregulated in LUSC tissues and serum relative to the control group. The A allele at rs9914618 was positively associated with increased LINC00673 transcription. Carriers of the A allele or AA genotype had a higher risk of LUSC. Patients with GA or AA genotypes showed more severe clinicopathological features and lower five‑year survival rates. The rs9914618 polymorphism was validated as an independent prognostic factor.</p><p><strong>Conclusion: </strong>The LINC00673 rs9914618 polymorphism may serve as a potential prognostic factor for LUSC, showing significant associations with patient outcomes and risk stratification.</p>","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":" ","pages":"863-872"},"PeriodicalIF":4.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148817832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}